News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inflabloc Pharmaceuticals Inc. Closes $6 Million Series C Financing And Merger With MantiCore Pharmaceuticals Inc.



2/9/2006 10:41:28 AM

SALT LAKE CITY--(BUSINESS WIRE)--Feb. 9, 2006--Inflabloc Pharmaceuticals Inc. announced today that it had successfully completed a $6 million Series C venture financing. This financing coincides with the completion of the merger with MantiCore Pharmaceuticals Inc. and was co-led by Friedli Corporate Finance and vSpring Capital. Inflabloc will use the financing to further its Phase II clinical studies of its lead product targeting inflammatory diseases, as well as continue early-stage development in oncological diseases.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES